CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy and Safety of DA-8010, a Novel M3 Antagonist, in Patients With Overactive Bladder: A Randomized, Double-Blind Phase 2 Study
Hee Seo Son, Cheol Young Oh, Myung-Soo Choo, Hyeong Gon Kim, Joon Chul Kim, Kyu-Sung Lee, Dong Gil Shin, Sung Yong Cho, Seong Jin Jeong, Ju Tae Seo, Hana Yoon, Hong Sang Moon, Jang Hwan Kim
Int Neurourol J. 2022;26(2):119-128.   Published online 2022 June 30
DOI: https://doi.org/10.5213/inj.2142382.191

Excel Download

Efficacy and Safety of DA-8010, a Novel M3 Antagonist, in Patients With Overactive Bladder: A Randomized, Double-Blind Phase 2 Study
International Neurourology Journal. 2022;26(2):119-128   Crossref logo
Link1 Link2 Link3

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder
Yearbook of Urology. 2014;2014:68-69   Crossref logo
Link1 Link2

A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder
International Journal of Urology. 2008;15(9):809-815   Crossref logo
Link1 Link2

Efficacy and Safety of Oxybutynin Chloride Topical Gel for Overactive Bladder: A Randomized, Double-Blind, Placebo Controlled Multicenter Study
Yearbook of Urology. 2010;2010:36-37   Crossref logo
Link1 Link2

Re: Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)
European Urology. 2015;67(6):1189-1190   Crossref logo
Link1 Link2

A Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Oxybutynin Vaginal Ring for Alleviation of Overactive Bladder Symptoms in Women
Journal of Urology. 2014;191(4):1014-1021   Crossref logo
Link1 Link2 Link3

Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder
Current Therapeutic Research. 2009;70(6):405-420   Crossref logo
Link1 Link2

Efficacy and Safety of 10 mg Solifenacin Succinate in Patients with Overactive Bladder Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Pivotal Trial
Clinical Medicine Insights: Urology. 2010;4:CMU.S4960   Crossref logo
Link1 Link2 Link3

Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial
Yearbook of Urology. 2011;2011:25-26   Crossref logo
Link1 Link2

Editorial Comment to Efficacy of novel β 3 ‐adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post‐hoc analysis of a randomized, double‐blind, placebo‐controlled phase 3 study
International Journal of Urology. 2018;26(3):375-376   Crossref logo
Link1 Link2 Link3 Link4